×
Allocating scarce intensive care resources during the COVID-19 pandemic: practical chal...
https://doi.org/10.1016/S2213-2600(20)30580-4
The Lancet. Respiratory Medicine; Supady A, Curtis JR et. al.

Jan 15th, 2021 - The COVID-19 pandemic strained health-care systems throughout the world. For some, available medical resources could not meet the increased demand and rationing was ultimately required. Hospitals and governments often sought to establish triage committees to assist with allocation decisions. However, for institutions operating under crisis standards of care (during times when standards of care ...

Vitamin D, zinc and glutamine: Synergistic action with OncoTherad immunomodulator in in...
https://doi.org/10.3892/ijmm.2021.4844
International Journal of Molecular Medicine; Name JJ, Vasconcelos AR et. al.

Jan 15th, 2021 - Coronavirus disease 2019 (COVID‑19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), was identified in December, 2019 in Wuhan, China. Since then, it has continued to spread rapidly in numerous countries, while the search for effective therapeutic options persists. Coronaviruses, including SARS‑CoV‑2, are known to suppress and evade the antiviral responses of the host or...

COVID-19: What Should the General Practitioner Know?
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7800435
Clinical Interventions in Aging; Grygiel-Górniak B, Oduah MT

Jan 14th, 2021 - SARS-CoV-2 infection is currently the most significant public health challenge. Its presentation ranges from mild to severe respiratory failure and septic shock. Rapid transmission of the virus is dangerous with a high possibility of life-threatening complications. Lack of treatment standards for SARS-CoV-2 is responsible for the current dilemma in clinical medicine. An electronic literature se...

Immunoinformatics-guided Designing and In Silico Analysis of Epitope-based Polyvalent V...
https://doi.org/10.1080/14760584.2021.1874925
Expert Review of Vaccines; Sarkar B, Ullah A et. al.

Jan 13th, 2021 - Objectives: The group of human coronaviruses (HCoVs) consists of some highly pathogenic viruses that have caused several outbreaks in the past. The newly emerged strain of HCoV, the SARS-CoV-2 is responsible for the recent global pandemic that has already caused the death of hundreds of thousands of people due to the lack of effective therapeutic options. Methods: In this study, immunoinformati...

A Comprehensive Systematic Review of CSF analysis that defines Neurological Manifestati...
https://doi.org/10.1016/j.ijid.2021.01.002
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases; Tandon M, Kataria S et. al.

Jan 12th, 2021 - Limited literature exists on CSF findings in COVID-19 patients with neurological symptoms. In this review, we conducted a descriptive analysis of CSF findings in patients with COVID-19 to understand prognosis and explore therapeutic options. We searched PubMed, Google Scholar and Scopus databases using the keywords "SARS-CoV-2 in cerebrospinal fluid", "SARS-CoV-2 and CNS Complications"" for rep...

The 2020 race towards SARS-CoV-2 specific vaccines.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778607
Theranostics Karpiński TM, Ożarowski M et. al.

Jan 7th, 2021 - The global outbreak of a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlighted a requirement for two pronged clinical interventions such as development of effective vaccines and acute therapeutic options for medium-to-severe stages of "coronavirus disease 2019" (COVID-19). Effective vaccines, if successfully developed, have been emphasized to become the most effective s...

Pragmatic Recommendations for Therapeutics of Hospitalized COVID-19 Patients in Low- an...
https://doi.org/10.4269/ajtmh.20-1106
The American Journal of Tropical Medicine and Hygiene; Shetty VU, Brotherton BJ et. al.

Dec 30th, 2020 - The therapeutic options for COVID-19 patients are currently limited, but numerous randomized controlled trials are being completed, and many are on the way. For COVID-19 patients in low- and middle-income countries (LMICs), we recommend against using remdesivir outside of a clinical trial. We recommend against using hydroxychloroquine ± azithromycin or lopinavir-ritonavir. We suggest empiric an...

Natural history of COVID-19 and therapeutic options.
https://doi.org/10.1080/1744666X.2021.1847640
Expert Review of Clinical Immunology; Gautret P, Million M et. al.

Dec 28th, 2020 - Introduction: COVID-19 presents benign forms in young patients who frequently present with anosmia. Infants are rarely infected, while severe forms occur in patients over 65 years of age with comorbidities, including hypertension and diabetes. Lymphopenia, eosinopenia, thrombopenia, increased lactate dehydrogenase, troponin, C-reactive protein, D-dimers and low zinc levels are associated with s...

Convalescent plasma may be a possible treatment for COVID-19: A systematic review.
https://doi.org/10.1016/j.intimp.2020.107262
International Immunopharmacology; Wang Y, Huo P et. al.

Dec 18th, 2020 - The coronavirus disease 2019 (COVID-19) pandemic has spread globally. Therapeutic options including antivirals, anti-inflammatory compounds, and vaccines are still under study. Convalescent plasma(CP) immunotherapy was an effective method for fighting against similar viral infections such as SARS-CoV, and MERS-CoV. In the epidemic of COVID-19, a large number of literatures reported the applicat...

Relevance of the Bruton Tyrosine Kinase (BTK) as a target for COVID-19 therapy.
https://doi.org/10.1158/1541-7786.MCR-20-0814
Molecular Cancer Research : MCR; Rada M, Qusairy Z et. al.

Dec 17th, 2020 - The outbreak of the novel coronavirus disease 2019 (COVID-19) has emerged as one of the biggest global health threats worldwide. As of October 2020, over 44 million confirmed cases and more than 1,160,000 deaths have been reported globally, and the toll is likely to be much higher before the pandemic is over. There are currently little therapeutic options available and new potential targets are...

Synergistic and Antagonistic Drug Combinations against SARS-CoV-2.
https://doi.org/10.1016/j.ymthe.2020.12.016
Molecular Therapy : the Journal of the American Society of Gene Therapy; Bobrowski T, Chen L et. al.

Dec 17th, 2020 - Antiviral drug development for coronavirus disease 2019 (COVID-19) is occurring at an unprecedented pace, yet there are still limited therapeutic options for treating this disease. We hypothesized that combining drugs with independent mechanisms of action could result in synergy against SARS-CoV-2, thus generating better antiviral efficacy. Using in silico approaches, we prioritized 73 combinat...

Integrating Proteomics for Facilitating Drug Identification and Repurposing During an E...
https://doi.org/10.1021/acsinfecdis.0c00579
ACS Infectious Diseases; Schindell BG, Allardice M et. al.

Dec 15th, 2020 - The coronavirus disease 2019 (COVID-19) pandemic has disrupted global healthcare and economic systems throughout 2020 with no clear end in sight. While the pandemic continues to have deleterious effects across the globe, mechanisms for disrupting disease transmission have relied on behavioral controls (e.g., social distancing, masks, and hygiene) as there are currently no vaccines approved for ...

An umbrella review of systematic reviews with meta-analyses evaluating positive and neg...
https://doi.org/10.1016/j.ijid.2020.12.018
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases; Celotto S, Veronese N et. al.

Dec 14th, 2020 - Hydroxychloroquine (HCQ) and chloroquine (CQ) are anti-malarial drugs frequently used in the rheumatologic field. Recently they were identified as possible therapeutic options against Coronavirus Disease (COVID-19). Therefore, the present study aimed to map and grade the diverse health outcomes associated with HCQ/CQ using an umbrella review approach. Umbrella review of systematic reviews of ob...

RSNA International Trends: A Global Perspective on the COVID-19 Pandemic and Radiology ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734846
Radiology Tan BS, Dunnick NR et. al.

Dec 8th, 2020 - The COVID-19 pandemic has challenged and changed our healthcare systems around the world. There has been a heterogeneity of disease burden, healthcare resources, and non-imaging testing availability, both geographically and over time. In parallel, there has been a continued increase in understanding of how the disease affects patients, effectiveness of therapeutic options, and factors that modu...

Evidence for treatment with estradiol for women with SARS-CoV-2 infection.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685778
BMC Medicine; Seeland U, Coluzzi F et. al.

Nov 25th, 2020 - Given that an individual's age and gender are strongly predictive of coronavirus disease 2019 (COVID-19) outcomes, do such factors imply anything about preferable therapeutic options? An analysis of electronic health records for a large (68,466-case), international COVID-19 cohort, in 5-year age strata, revealed age-dependent sex differences. In particular, we surveyed the effects of systemic h...

First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710192
Medicine Chen H, Zhang Z et. al.

Nov 25th, 2020 - As coronavirus disease 2019 (COVID-19) outbreak globally, repurposing approved drugs is emerging as important therapeutic options. Danoprevir boosted by ritonavir (Ganovo) is a potent hepatitis C virus (HCV) protease (NS3/4A) inhibitor, which was approved and marketed in China since 2018 to treat chronic hepatitis C patients. This is an open-label, single arm study evaluating the effects of dan...

Structure of nonstructural protein 1 from SARS-CoV-2.
https://doi.org/10.1128/JVI.02019-20
Journal of Virology; Clark LK, Green TJ et. al.

Nov 25th, 2020 - The periodic emergence of novel coronaviruses (CoVs) represents an ongoing public health concern with significant health and financial burden worldwide. The most recent occurrence originated in the city of Wuhan, China where a novel coronavirus (SARS-CoV-2) emerged causing severe respiratory illness and pneumonia. The continual emergence of novel coronaviruses underscores the importance of deve...

Malignant Bowel Obstruction in the Time of the COVID-19 Pandemic.
https://doi.org/10.1177/0003134820973028
The American Surgeon; Fallon EA, Miner TJ

Nov 24th, 2020 - Regardless of the anatomic site of malignant bowel obstruction leading to the need for palliative intervention, decisions must consider the natural history of the disease, the availability and success of nonsurgical treatments, the individual patient's symptom severity, goals, preferences, quality, and expectancy of life. Therapy for symptoms must remain flexible and individualized because the ...

The unusual experience of managing a severe COVID-19 case at home: what can we do and w...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675380
BMC Infectious Diseases; Chérrez-Ojeda I, Vanegas E et. al.

Nov 20th, 2020 - The speed and reach of the COVID-19 pandemic has created special scenarios to be considered, such as those in where patients who meet criteria for hospitalization due to moderate/severe disease cannot be hospitalized due to economic constraints and saturation of national health systems. The aim of this report is to present an unusual case of a severe COVID-19 patient managed at home in a develo...

Designing therapeutic strategies to combat severe acute respiratory syndrome coronaviru...
https://doi.org/10.1002/ddr.21720
Drug Development Research REFERENCES; Rohilla S

Nov 20th, 2020 - A highly contagious coronavirus disease COVID-19 caused by a recently identified severe acute respiratory syndrome CoV-2 (SARS-CoV-2) initially detected in Wuhan, China has spread worldwide and become a major health crisis in the absence of specific vaccine or antiviral drugs. SARS-CoV-2 infection has resulted in overwhelming number of reported deaths. Unfortunately it is still spreading uncont...